MENA Biologics & Biosimilars Market, By Product Type (Influenza Vaccines, Factor VIII ( Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate, Novoeight), Erythropoietin (Epoetin Alfa (Pr

MENA Biologics & Biosimilars Market, By Product Type (Influenza Vaccines, Factor VIII ( Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate, Novoeight), Erythropoietin (Epoetin Alfa (Procrit, Epogen), Darbepoietin Alfa (Aranesp), Epoetin Alfa-epbx (Retacrit)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP))), By Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), By Geography (Gulf and Egypt)

MENA Biologics & Biosimilars Market, By Product Type (Influenza Vaccines, Factor VIII ( Xyntha, Octanate, Kovaltry, Advate, Koate, Adynovate, Kogenate, Hemlibra, Elocta, Recombinate, Feiba, Immunate, Alphanate, Novoeight), Erythropoietin (Epoetin Alfa (Procrit, Epogen), Darbepoietin Alfa (Aranesp), Epoetin Alfa-epbx (Retacrit)), Aflibercept (EYLEA), and Ziv-Aflibercept (ZALTRAP))), By Therapeutic Application (Hemophilia, Age-related Macular Degeneration, Kidney Diseases, Influenza, and Others), By Geography (Gulf and Egypt)

Biologics, or biological products, are medicines that are made from living organisms through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, blood products, cytokines, growth factors, fusion proteins, insulin, interferon, and vaccines. Biologics are used to prevent, treat, or cure various diseases including cancer, chronic kidney disease, diabetes, cystic fibrosis, and autoimmune disorders. It improves health in many complex conditions including crohn’s disease, ulcerative colitis, diabetes, rheumatoid arthritis, cancer, osteoporosis, psoriasis, HIV, multiple sclerosis, growth deficiencies, and others. In the ever-evolving pharmaceuticals and biotechnology, the concept of biologic localization has gained popularity. The Kingdom of Saudi Arabia, driven by its Vision 2030 framework, aspires to establish itself as a global biologics manufacturing hub.

Market Dynamics

The healthcare sector of Saudi Arabia is witnessing significant reforms, owing to increasing initiatives by governments, agreements between multinational pharmaceutical companies, and rising healthcare expenditures. Rapid reforms in the healthcare sector in Saudi Arabia by the government and multinational companies is expected to propel growth of the MENA biologics & biosimilars market. For instance, in March 2020, the Ministry of Health (MOH) of Saudi Arabia signed a memorandum of understanding with Sanofi, a pharmaceutical and healthcare company in Saudi Arabia to start localizing and transferring insulin industry technology locally in the Kingdom of Saudi Arabia and exploring the possibility of external exports to the GCC countries and the Middle East region. The memorandum included, the availability of diabetes medications in the Kingdom, and providing innovative healthcare solutions to treat and reduce diabetes complications in the Kingdom.

Key features of the study:

• This report provides an in-depth analysis of the MENA biologics & biosimilars market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the MENA biologics & biosimilars market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Sanofi, and Amgen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• MENA biologics & biosimilars market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the MENA biologics & biosimilars market

MENA Biologics & Biosimilars Market Detailed Segmentation:

• By Product Type:
• Influenza Vaccines
• Factor VIII

Xyntha

Octanate

Kovaltry

Advate

Koate

Adynovate

Kogenate

Hemlibra

Elocta

Recombinate

Feiba

Immunate

Alphanate

Novoeight

• Erythropoietin

Epoetin Alfa (Procrit, Epogen)

Darbepoietin Alfa (Aranesp)

Epoetin Alfa-epbx (Retacrit)

• Aflibercept (EYLEA)
• Ziv-Aflibercept (ZALTRAP)
• By Therapeutic Application:
• Hemophilia
• Age-Related Macular Degeneration
• Kidney Diseases
• Influenza
• Others
• By Region/Country:
• GULF
• Saudi Arabia
• UAE
• Kuwait
• Egypt
• Company Profiles
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
• Sanofi
• Amgen Inc.